Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als entities : Eagle pharmaceuticals, inc. save search
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results
Published: 2022-03-07 (Crawled : 12:00) - globenewswire.com
TYME | $0.3107 -8.21%
|
Health Technology
|
| O: -4.78%
H: 3.2%
C: 0.21%
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
als report results
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022
Published: 2022-02-24 (Crawled : 12:00) - globenewswire.com
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -0.92%
H: 0.5%
C: 0.11%
als financial results results
Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™
Published: 2022-02-01 (Crawled : 12:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.37%
H: 0.0%
C: 0.0%
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: 2.56%
H: 0.0%
C: -1.08%
als commercialization
Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
Published: 2022-01-31 (Crawled : 16:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
new drug als application drug submission
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -2.04%
H: 1.36%
C: -2.06%
als commercialization
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
Published: 2021-12-29 (Crawled : 21:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -0.08%
H: 0.38%
C: -1.21%
als
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
Published: 2021-12-20 (Crawled : 17:00) - eagleus.com
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -0.46%
H: 4.1%
C: 2.46%
als
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
Published: 2021-12-15 (Crawled : 21:00) - eagleus.com
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.69%
fda als fda approval approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.